Literature DB >> 20837008

Allosteric rescuing of loss-of-function FFAR2 mutations.

Gayathri Swaminath1, Peter Jaeckel, Qi Guo, Mario Cardozo, Jennifer Weiszmann, Richard Lindberg, Yingcai Wang, Ralf Schwandner, Yang Li.   

Abstract

FFAR2 (GPR43) is a receptor for short-chain fatty acids (SCFAs), acetate and propionate. In the current study, we investigate the molecular determinants contributing to receptor activation by endogenous ligands. Mutational analysis revealed several important residues located in transmembrane domains (TM) 3, 4, 5, 6, and 7 for acetate binding. Interestingly, mutations that abolished acetate activity, including the mutation in the well-conserved D(E)RY motif, could be rescued by a recently identified synthetic allosteric agonist. These findings provide additional insight into agonist binding and activation which may aid in designing allosteric ligands for targeting receptor function in various diseases.
Copyright © 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20837008     DOI: 10.1016/j.febslet.2010.09.007

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

Review 1.  The therapeutic potential of GPR43: a novel role in modulating metabolic health.

Authors:  Lauren M Cornall; Michael L Mathai; Deanne H Hryciw; Andrew J McAinch
Journal:  Cell Mol Life Sci       Date:  2013-07-14       Impact factor: 9.261

2.  Characterisation of small molecule ligands 4CMTB and 2CTAP as modulators of human FFA2 receptor signalling.

Authors:  Zoe V Schofield; Daniel Croker; Avril A B Robertson; Nicholas L Massey; Chantal Donovan; Ernest Tee; David Edwards; Trent M Woodruff; Reena Halai; Philip M Hansbro; Matthew A Cooper
Journal:  Sci Rep       Date:  2018-12-13       Impact factor: 4.379

3.  Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets.

Authors:  Trond Ulven
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-02       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.